

Subcommittee Name: PTCOG H&N Subcommittee

Co-chairs

Name	Country	Term started	Term ends*
Steven J. Frank, MD	USA	June 2021	June 2027*
JA Langendijk, MD	Amsterdam	June 2024	June 2030
Shinichiro Mori, PhD	Japan	June 2024	June 2027**

* The term of office is 3 years and may be renewed once, for a maximum total service of 6 years. It is recommended that the 3 co-chairs come from 3 different continents (America, Asia, Europe). To ensure continuity, it is recommended that the co-chairs step down on a staggered basis following their first three-year term.

**Dr. Shinichiro (Co-Chair) will be up for renewal of term if he chooses to stay on for a second term; Dr. Frank is the current Chair and rotates off after 2 terms; Dr. Langendijk (Co-Chair) will start his second term and serve as Chair as Dr. Frank rotates off.

Subcommittee Achievements

The Head and Neck Subcommittee has been very productive with prolific academic collaborative achievements that have defined proton therapy as a new standard of care for head and neck tumors.



1. Dr. Frank was the editor for the special issue 'Particle Therapy for Head and Neck Malignancies' International Journal of Particle Therapy. Volume 8 (1) 2021 <https://doi.org/10.14338/2331-5180-8.1.1>
2. **34** published articles on particle therapy for head and neck malignancies in the *IJPT* special edition
3. **2** Phase III Randomized Trials on Oropharyngeal Tumors comparing IMPT vs IMRT in United States and United Kingdom published in *The Lancet* 2026 (Frank SJ – US) (Thompson D – UK)
4. **1** Phase III trial ongoing in Denmark on IMPT vs IMRT for head and neck tumors
5. **1** Phase II trial ongoing in Sweden on IMPT vs IMRT for head and neck tumors
6. 2026: Multi-institution head and neck planning study with IMPT for quality assurance (JW Snider)
7. 2026: Dosimetry/Physics manuscript on US Phase III Trial of IMPT vs IMPT (Zhang X)
8. 2026: Cost-effectiveness analysis on US Phase III Trial of IMPT vs IMRT for OPC (Iakovos)
9. (Thariat J) Organized PTCOG 64; ongoing Phase II trial in sinonasal cancers and ongoing Phase III trial with post-op flaps, 15 publications

Do you maintain a mailing list of subcommittee members (Yes/No)? Yes

Should the subcommittee continue its work (Yes/No)? Yes

If yes, please describe the planned activities and goals for the next 3 years – max 2,000 characters including spaces

There are substantive planned activities over the next 3 years.

1. 2026-2029: Proton Therapy Academy and HN Subcommittee Working Group –
5 White Papers on the management of oropharyngeal tumors by vendor; Hitachi, IBA, Mevion, Varian, and P-Cure. This will ensure that consistent high-quality treatment plans are obtained to provide best protons plans for patients.
2. Complete 2 randomized trials of IMPT vs IMRT for head and neck tumors
3. Perform a meta-analysis of IMPT vs IMRT for head and neck tumors with the **4** randomized clinical trials (Blanchard P)
4. Collaboration with EPTN and HN subcommittee on optimal treatment planning based on model-based approach.

Please circulate this form to all subcommittee members and once agreed upon by the subcommittee submit it to: secretariat@ptcog.online (cc: m.durante@gsi.de) within:

August 30, 2026

Please attach the list of subcommittee members (name and country).

The information contained in this form and the list of members will be uploaded on the webpage of your subcommittee (see: <https://ptcog.online/subcommittee/>).